

Pranatharthi H Chandrasekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7551305/publications.pdf>

Version: 2024-02-01

63
papers

8,448
citations

257101

24
h-index

138251

58
g-index

63
all docs

63
docs citations

63
times ranked

5008
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature. Expert Opinion on Pharmacotherapy, 2022, , 1-7.	0.9	4
2	Favorable outcome of COVID-19 among African American (AA) renal transplant recipients in Detroit. Clinical Transplantation, 2021, 35, e14169.	0.8	5
3	Azole resistance in Aspergillus species: promising therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1-8.	0.9	5
4	Striking absence of "usual suspects" during the winter of the coronavirus disease 2019 (COVID-19) pandemic 2020-2021. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.0	1
5	Spontaneous Hemoptysis in a Patient With COVID-19. Chest, 2021, 160, e39-e44.	0.4	3
6	SARS-CoV-2 infection: Initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. PLoS ONE, 2021, 16, e0255981.	1.1	29
7	Carbapenem-Susceptible Klebsiella pneumoniae and Escherichia coli Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics. Journal of Clinical Microbiology, 2020, 58, .	1.8	4
8	Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine. Open Forum Infectious Diseases, 2020, 7, ofaa274.	0.4	8
9	Evaluation of Susceptibility and Innate Immune Response in C57BL/6 and BALB/c Mice During Candida albicans Endophthalmitis. , 2020, 61, 31.		5
10	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 36.	1.5	15
11	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clinical Infectious Diseases, 2020, 71, 2365-2374.	2.9	36
12	Pre-exposure Prophylaxis in HIV: Is it Time to Act Now?. Journal of the Association of Physicians of India, The, 2020, 68, 89.	0.0	0
13	Invasive aspergillosis in patients following umbilical cord blood transplant. Bone Marrow Transplantation, 2019, 54, 308-311.	1.3	4
14	Pathobiology of Aspergillus Fumigatus Endophthalmitis in Immunocompetent and Immunocompromised Mice. Microorganisms, 2019, 7, 297.	1.6	21
15	Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy. Open Forum Infectious Diseases, 2019, 6, ofz037.	0.4	15
16	Infectious Complications of Cryoablation and Microwave Ablation in Metastatic Solid Tumors. Infection Control and Hospital Epidemiology, 2018, 39, 723-726.	1.0	1
17	Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. Mycoses, 2018, 61, 331-336.	1.8	8
18	Hyperpigmented Macule on the Palm and Diminished Sensation. JAMA - Journal of the American Medical Association, 2018, 320, 2029.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Isavuconazole for Treatment of Experimental Fungal Endophthalmitis Caused by <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
20	Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2017, 25, 2593-2601.	1.0	11
21	<i>Candida auris</i> : a worrisome, globally emerging pathogen. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 819-827.	2.0	64
22	Hemophagocytic lymphohistiocytosis (HLH): Elusive diagnosis of disseminated <i>Mycobacterium avium</i> complex infection. <i>Germes</i> , 2017, 7, 149-152.	0.5	4
23	Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. <i>Infection and Drug Resistance</i> , 2016, Volume 9, 291-300.	1.1	52
24	Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient. <i>Leukemia and Lymphoma</i> , 2016, 57, 2693-2695.	0.6	0
25	Adverse effects of voriconazole: Over a decade of use. <i>Clinical Transplantation</i> , 2016, 30, 1377-1386.	0.8	96
26	<i>Clostridium Difficile</i> Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 157-163.	2.0	59
27	Bad News to Worse News: 2015 Infectious Diseases Fellowship Match Results. <i>Clinical Infectious Diseases</i> , 2015, 60, 1438.	2.9	12
28	Voriconazole toxicity masquerading as septic shock. <i>Leukemia and Lymphoma</i> , 2015, 56, 1170-1171.	0.6	2
29	Infectious Diseases Subspecialty: Declining Demand Challenges and Opportunities. <i>Clinical Infectious Diseases</i> , 2014, 59, 1593-1598.	2.9	41
30	Management of gram-positive bacterial infections in patients with cancer. <i>Leukemia and Lymphoma</i> , 2012, 53, 8-18.	0.6	34
31	Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. <i>Infection and Drug Resistance</i> , 2012, 5, 9.	1.1	19
32	Management of invasive fungal infections: a role for polyenes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 457-465.	1.3	76
33	Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B. <i>Medicine (United States)</i> , 2010, 89, 236-244.	0.4	81
34	Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis. <i>Current Fungal Infection Reports</i> , 2010, 4, 30-37.	0.9	0
35	Diagnostic challenges and recent advances in the early management of invasive fungal infections. <i>European Journal of Haematology</i> , 2010, 84, 281-290.	1.1	43
36	<i>Clostridium difficile</i> infection in cancer patients and hematopoietic stem cell transplant recipients. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1113-1119.	2.0	75

#	ARTICLE	IF	CITATIONS
37	Antifungal drugs: predicting clinical efficacy with pharmacodynamics. Expert Review of Clinical Pharmacology, 2009, 2, 373-379.	1.3	3
38	Treatment of breakthrough fungal infections: Is there one best drug strategy?. Current Fungal Infection Reports, 2009, 3, 229-235.	0.9	5
39	Prophylaxis against <i>Aspergillus</i> is not perfect: problems and perils in stem cell transplantation. Medical Mycology, 2009, 47, S349-S354.	0.3	6
40	Invasive mold infections: recent advances in management approaches. Leukemia and Lymphoma, 2009, 50, 703-715.	0.6	28
41	Current and Future Therapeutic Options in the Management of Invasive Aspergillosis. Drugs, 2008, 68, 265-282.	4.9	16
42	Do <i>Aspergillus</i> species produce biofilm?. Future Microbiology, 2008, 3, 19-21.	1.0	21
43	Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. Transplantation, 2008, 86, 183-191.	0.5	4
44	Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1285-1294.	0.9	9
45	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clinical Infectious Diseases, 2007, 44, 2-12.	2.9	724
46	Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. New England Journal of Medicine, 2007, 356, 335-347.	13.9	1,228
47	Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. Pharmacotherapy, 2007, 27, 1627-1636.	1.2	163
48	Selection criteria for antifungals: the right patients and the right reasons. International Journal of Antimicrobial Agents, 2006, 27, 17-20.	1.1	7
49	The experience is CLEAR®. International Journal of Antimicrobial Agents, 2006, 27, 31-35.	1.1	3
50	A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of <i>Aspergillus fumigatus</i> . Journal of Antimicrobial Chemotherapy, 2005, 55, 914-920.	1.3	40
51	Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2005, 40, S392-S400.	2.9	66
52	Riches usher dilemmas: Antifungal therapy in invasive aspergillosis. Biology of Blood and Marrow Transplantation, 2005, 11, 77-84.	2.0	4
53	Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial. Annals of Internal Medicine, 2003, 138, 705.	2.0	351
54	A Double-blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2002, 35, 359-366.	2.9	308

#	ARTICLE	IF	CITATIONS
55	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	13.9	3,048
56	Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). , 1999, 61, 194-202.		126
57	Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin*. Clinical Pharmacology and Therapeutics, 1995, 58, 617-624.	2.3	78
58	Foscarnet Therapy for Acyclovir-Resistant Herpes Simplex Virus 1 Infection in Allogeneic Bone Marrow Transplant Recipients. Clinical Infectious Diseases, 1995, 21, 1514-1515.	2.9	21
59	Immune globulin use at a multihospital medical center. American Journal of Health-System Pharmacy, 1994, 51, 801-805.	0.5	1
60	The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Journal of Antimicrobial Chemotherapy, 1994, 33, 309-318.	1.3	63
61	A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. New England Journal of Medicine, 1992, 326, 845-851.	13.9	1,175
62	Pneumocystis cariniiPneumonia in patients with solid tumors without acquired immune deficiency syndrome. Cancer, 1991, 68, 193-194.	2.0	9
63	Bone and Joint Infections in Intravenous Drug Abusers. Clinical Infectious Diseases, 1986, 8, 904-911.	2.9	84